Vertellus Relocates Mumbai Office to Accommodate Growth

© totojang1977/Shutterstock
© totojang1977/Shutterstock

Vertellus, a global specialty chemical provider, has relocated its Mumbai, India, office to a larger commercial space within the city. The inauguration ceremony for the new site took place on Jan. 22.

Operations at the new location are managed by K.S. Shivanand, Vertellus commercial director for South Asia and the Middle East. The staff based in Mumbai market the full range of the company’s offerings including fine chemicals, specialty chemicals and plastic additives. Vertellus products serve customers in a variety of industries including pharmaceuticals, agriculture, nutrition, personal care, plastics and industrial manufacturing.

“The new space accommodates the addition of staff over the past four years and positions us to add to our team in the future,” said Shivanand. “Like many multinational companies around the globe, Vertellus is investing in India’s fast-growing economy and leveraging opportunities to serve rapidly expanding industrial segments. The new facility reflects Vertellus’ ongoing commitment to the region.”

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.